Loading clinical trials...
Loading clinical trials...
PET Imaging With 89Zr-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness
Our goal is to investigate the use of 89Zr-trastuzumab as a HER2 imaging agent to determine which patients are likely to respond to targeted HER2 agents as single agent therapy. We are proposing to perform a pilot study with goals of demonstrating the feasibility of imaging breast cancer patients with 89Zr-trastuzumab-PET/MRI, evaluating the relationship between tumor 89Zr-trastuzumab uptake and in vitro positivity of HER2, assessing the relationship between 89Zr-trastuzumab uptake and response to HER2 therapy.
Age
18 - No limit years
Sex
FEMALE
Healthy Volunteers
No
The Kirklin Clinic
Birmingham, Alabama, United States
Start Date
November 21, 2017
Primary Completion Date
October 1, 2028
Completion Date
October 1, 2028
Last Updated
January 26, 2026
10
ESTIMATED participants
[89Zr]-Df-Trastuzumab
DRUG
PET/MRI Imaging
DIAGNOSTIC_TEST
Lead Sponsor
University of Alabama at Birmingham
NCT05372640
NCT04704661
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions